Drilldown: Medicines

None (2) · Tamsulosin (1)

Flomax (1) · Kisunla (1) · Rexulti (1)

5HT1A activity than aripiprazole (1) · 5HT2A (1) · Anti-amyloid beta (Aβ) monoclonal antibody (1) · Atypical antipsychotic (1) · D2/5HT1A partial agonist with stronger α1A (1) · targets pyroglutamated Aβ in plaques (1) · [[:Category:Alpha-1_blockers|Alpha-1A adrenergic blocker]] (1) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1)

None (2) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1)

Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · '"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"' (1)

0.4 mg PO once daily, 30 minutes after the same meal each day (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)

None · 10 mg, 20 mg, 40 mg, 80 mg tablets · 2.5, 5, 10, 20 mg tabs · 5 mg, 10 mg tablets · 5, 10 mg tablets · 5, 10, 20, 40 mg tablets · 0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle · 0.01%, 0.03% ophthalmic solution · 0.025%, 0.035% ophthalmic solutions · 0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray · 0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) · 0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) · 0.225%, 0.45%, 0.9%, 3%, 5% IV solutions; 0.9% nasal spray; 3% and 7% nebulizer solutions; oral tablets (1 g) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets · 0.25, 0.5 mcg oral capsules; 1 mcg/mL oral solution; 1 mcg/mL IV; 3 mcg/g topical ointment · 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT · 0.4 mg capsules · 0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection · 0.5 g, 1 g capsules

Other values:

Search

0.8 mg/d (rarely needed) (1) · 1400 mg q4w (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1)

IV infusion every 4 weeks (1) · Oral (2)

Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Symptom improvement within 1 week; peak effect at 4-6 weeks (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)

24 hours (1) · Daily dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1)

9-15 hours'"`UNIQ--ref-000001BC-QINU`"' (1) · ~12.1 days (1) · ~91 hours (1)

100% (IV) (1) · >90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1) · ~95% (1)

Limited data (1) · Limited data; National Pregnancy Registry available (1) · Not applicable (male indication); historical Category B if used in unrelated female cases.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (1) · Rx; ARIA monitoring required (1) · [[USLegal:Prescription only|Rx-only]] in US (1)